Invoking for the first time a provision “in public interest’’, the drug prices regulator NPPA on Friday revised prices of 21 formulations, allowing a one-time increase of 50% from the existing ceiling price. The NPPA’s move is in response to the pharma industry’s requests over the last two years to allow upward revision in prices.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/2RTQaCn
